title: [The physiology of incretins].
abstract: The discovery of incretins-glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrop peptide (GIP)-, clarification of their physiological properties as well as therapeutic application of incretin-based blood glucose lowering drugs opened new perspectives in the medical management of type 2 diabetes. New results of basic research investigations led to revaluation of the role of GIP in metabolic processes and a more established use of GLP-1 action. The article overviews the most relevant data of production and effects of incretins, as well as future possibilities of their therapeutic use.
authors.affiliation: Fovarosi Szent Janos Korhaz es Eszak-budai Egyesitett Intezmenyei, Budapest. gabor.winkler@janoskorhaz.hu
authors.forename: Gabor
authors.initials: G
authors.lastname: Winkler
mesh_terms: D000818:Animals; D003920:Diabetes Mellitus / Q000378:metabolism* / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D005749:Gastric Inhibitory Polypeptide / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D004763:Glucagon-Like Peptides / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D054795:Incretins / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism* / Q000502:physiology
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D005749:Gastric Inhibitory Polypeptide; D004763:Glucagon-Like Peptides